Results 121 to 130 of about 66,572 (262)

Massive Sampling Strategy for Antibody–Antigen Targets in CAPRI Round 55 With MassiveFold

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT Massive sampling with AlphaFold2 improves protein–protein complex predictions. This has been shown during the last CASP15‐CAPRI blind prediction round by the AFsample tool. However, more difficult targets including antibody–antigen binding remain challenging. CAPRI Round 55 consisted of three antibody–antigen targets and one heterotrimer.
Nessim Raouraoua, Marc F. Lensink, Guillaume Brysbaert   +2 more
wiley   +1 more source

Correlation between recognition of autologous tumor organoids by tumor-infiltrating lymphocytes from metastatic epithelial cancers and clinical response. [PDF]

J Immunother Cancer
Gustafson AM, Bhasin A, Gasmi B, Bui BD, Ade CM, Hanada KI, Halas HK, Gartner JJ, Prickett TD, Salazar J, Parkhust MR, Robbins P, Klemen ND, Kwong ML, Goff SL, Rosenberg SA, Yang JC.   +16 more
europepmc   +1 more source

Biomolecular Interaction Prediction in the Pre‐ and Post‐AlphaFold Era: The 8th CAPRI Evaluation

Proteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT We report on the 8th CAPRI Evaluation period, capturing the assessment of CAPRI Rounds 47 to 55 (excluding the CASP and COVID‐related Rounds), which have witnessed the transition to AI‐driven prediction tools such as AlphaFold and related alternatives. The prediction Rounds in this evaluation are characterized by a high level of difficulty due
Marc F. Lensink, Nessim Raouraoua, Guillaume Brysbaert, Sameer Velankar, Shoshana J. Wodak, Alexandre M. J. J. Bonvin   +5 more
wiley   +1 more source

Swine Leukocyte Antigen-12 Behaves Like a Swine Leukocyte Antigen Classical Class I Protein and is a Potential Xenoantigen in Humans. [PDF]

Transplant Direct
Gennuso VN, Wang ZY, Reyes LM, Tector M, Tector AJ.   +4 more
europepmc   +1 more source

A Multiple‐Model‐Informed Drug‐Development Approach for Optimal Regimen Selection of an Oncolytic Virus in Combination With Pembrolizumab

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 572-582, March 2025.
ABSTRACT The antitumor efficacy of an intratumoral injection of a genetically engineered oncolytic vaccinia virus carrying human IL‐7 and murine IL‐12 genes (hIL‐7/mIL‐12‐VV) was demonstrated in CT26.WT‐bearing mice. In the CT26.WT‐bearing mouse model, the efficacy of the combination of hIL‐7/mIL‐12‐VV plus the anti‐programmed cell death protein (PD)‐1
Akihiro Yamada, Mary P. Choules, Frances A. Brightman, Shigeru Takeshita, Shinsuke Nakao, Nobuaki Amino, Takeshi Nakayama, Masato Takeuchi, Kanji Komatsu, Fernando Ortega, Hitesh Mistry, David Orrell, Christophe Chassagnole, Peter L. Bonate   +13 more
wiley   +1 more source

HLA incompatibility mitigation strategies in off-the-shelf cancer immunotherapies: clinical implications and a practical framework for strategy selection and combination. [PDF]

Front Immunol
Das R, Askar M.
europepmc   +1 more source

Photo‐responsive carbon dots for pyroptosis‐mediated anti‐tumor application

Responsive Materials, EarlyView.
Photo‐responsive CDs generate ROS to induce tumor cell pyroptosis, thereby stimulating antitumor immunity. Abstract Pyroptosis refers to a kind of lytic programmed cell death, characterized by the release of pro‐inflammatory cytokines during the process. Owing to its immune response stimulation ability, pyroptosis has garnered considerable attention in
Lingyun Li, Xue Wu, Zekun Yan, Jun Wu, Caishi Huang, Songnan Qu   +5 more
wiley   +1 more source

Nanoparticle-mediated dual delivery of MHC class I and II antigens enhances T cell immunity and anti-tumor potency. [PDF]

Biomaterials
Li E, Butkovich N, Tucker JA, Nelson EL, Wang SW.   +4 more
europepmc   +1 more source

Cancer Vaccine Development: Toward Artificial Intelligence‐Assisted Personalized Cell Membrane Nanovaccine

Small, EarlyView.
Cancer nanovaccines have emerged as promising alternatives to conventional cancer vaccines, which have shown limited clinical efficacy. In particular, cell membrane nanoparticle‐based nanovaccines can offer high biocompatibility and immunogenicity while preserving tumor antigens, including antigen repertoires.
Munsik Kim, Ilkoo Noh
wiley   +1 more source

AlloPipe and Its Web Server Allogenomics: From Genomic Data to Candidate Minor Histocompatibility Antigens. [PDF]

HLA
Dhuyser A, Delaugère P, Laville P, Clerc R, Aarnink A, Mesnard L, Richard H.   +6 more
europepmc   +1 more source